Lymphadenopathy diagnostic criteria: Difference between revisions

Jump to navigation Jump to search
Amandeep Singh (talk | contribs)
WikiBot (talk | contribs)
m Bot: Removing from Primary care
Line 21: Line 21:
==References==
==References==
{{reflist|2}}
{{reflist|2}}
{{WH}}
{{WS}}


[[Category:primary care]]
[[Category:Inflammations]]
[[Category:Inflammations]]
[[Category:Dermatology]]
[[Category:Dermatology]]
[[Category:Hematology]]
[[Category:Hematology]]
[[Category:Physical examination]]
[[Category:Physical examination]]
{{WH}}
{{WS}}

Revision as of 22:35, 29 July 2020

Lymphadenopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Lymphadenopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT scan

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lymphadenopathy diagnostic criteria On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lymphadenopathy diagnostic criteria

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lymphadenopathy diagnostic criteria

CDC on Lymphadenopathy diagnostic criteria

Lymphadenopathy diagnostic criteria in the news

Blogs on Lymphadenopathy diagnostic criteria

Directions to Hospitals Treating Lymphadenopathy

Risk calculators and risk factors for Lymphadenopathy diagnostic criteria

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]

Overview

Diagnostic Criteria

Malignant Lymphadenopathy

Benign Lymphadenopathy

  • Node < 1 cm
  • Node that is mobile, soft-or tender, and is not fixed to underlying tissue
  • Common location (e.g. supraclavicular node)
  • No associated risk factors
  • Palpable and painful enlargement

References

Template:WH Template:WS